Latest Licensing Deals News

Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals secured European Commission approval for DAYBU (trofinetide) to treat Rett syndrome symptoms in patients aged five and older, marking the first EU-authorised treatment for this condition.

Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.

Yowie Group's revenue declined in the first half of 2026 as it navigated supply chain shifts and cautious retail demand, but the company secured a significant Australian licensing deal and ended costly legacy litigation.

Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.

Origin Energy reported a 6% increase in FY26 profit to $1.57 billion despite a 10% revenue drop, advancing renewable projects and extending Eraring Power Station operations, while managing a customer data breach.

EVE Health Group has progressed its Libbo pilot clinical study for erectile dysfunction with dosing set for Q4 2026 and achieved a major solubility breakthrough for apixaban, while appointing Ben Rohr as CEO to drive commercial growth.

Argent BioPharma's licensing partner Splash Beverage Group has launched the US veterinary development program for CannEpil®, targeting companion-animal oncology and chronic pain. Led by industry veteran Dr Hunter Land, the initiative follows a defined FDA regulatory pathway and could broaden CannEpil®’s commercial footprint beyond human neurology.

Acrux Limited spotlighted its Female Testosterone Metered Dose Transdermal System (MDTS) at the Bioshares Biotech Summit, revealing positive Phase II data and outlining a clear regulatory and commercial roadmap targeting Hypoactive Sexual Desire Disorder (HSDD) in women.

Dimerix CEO Dr Nina Webster detailed the company’s geographic and product diversification at the Bioshares Summit, spotlighting the commercial potential of DMX-200 and the newly acquired Phase 2 asset DMX-652 targeting acute kidney injury.

Acrux Limited’s FY26 receipts soared 960% to $5 million, fuelled by licensing milestones and growing generic sales, while FDA guidance clears the way for pivotal Phase III trials of its Female Testosterone therapy.

Dimerix Limited (ASX: DXB) has inked its fifth regional licensing agreement with Everest Medicines, boosting potential milestone payments to A$1.9 billion and expanded its kidney disease pipeline through the acquisition of DMX-652. The Phase 3 ACTION3 trial for DMX-200 remains statistically robust, with funding secured to advance both clinical programs.